A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
← catalyst calendarNCT04877288 · readout in 2,325 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
102estimated
Sites
38
Countries
Argentina, Belgium, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-21 | actual | When the study began enrolling |
| Primary completion | 2032-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Allograft Recipients
Interventions
- Biological: Belatacept — also filed as Nulojix
- Drug: Tacrolimus
- Drug: Cyclosporine A
- Drug: Mycophenolate Mofetil
- Drug: Enteric Coated Mycophenolate Sodium
- Drug: Corticosteroids
Primary outcome
what the primary-completion date above is the date OFProportion of participants who survive with a functional graft with estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 (updated Schwartz formula) at 24 months post-randomization
measured 24 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed